IntroDyno Therapeutics is at the forefront of revolutionizing gene therapy through the application of artificial intelligence (AI). Employing machine learning and advanced quantitative in vivo experimentation, we are innovating novel methodologies for crafting gene vectors, placing a specific emphasis on the cell-targeting capsid proteins derived from adeno-associated virus (AAV). AAV stands out as the predominant vector in gene therapies, and our approach aims to redefine the design process for enhanced efficacy.